Breast cancer regimen linked to cognitive decline

	Tweet

As a treatment for high-risk breast cancer patients, chemotherapy with high-dose cyclophosphamide, thiotepa, and carboplatin (CTC) is associated with a drop in cognitive performance over time, new research shows.

Previous reports have shown a drop in cognitive performance among breast cancer survivors treated with certain chemotherapy regimens, the researchers note in the Journal of the National Cancer Institute. However, there was a need to verify this observation in studies and to clarify which regimens produced the greatest cognitive deficits.

Dr. Sanne B. Schagen, from the Netherlands Cancer Institute in Amsterdam, and colleagues used standard tests to compare cognitive function in 28 patients treated with CTC, 39 patients treated with standard-dose 5-FU, epirubicin, and cyclophosphamide, 57 patients who received no chemotherapy, and 60 healthy comparison subjects.

Cognitive function was assessed in cancer patients before and 6 months after treatment (a 12-month interval) and in comparison subjects after a 6-month interval.

At initial testing, cognitive function was comparable in the four groups, the report indicates. At follow-up, however, 25 percent of CTC patients showed worsening cognitive function, while no significant changes occurred in women in the other treatment groups or the healthy subjects.

Executive functions, including skills such as planning, initiating behavior and being able to flexibly change activities, were the cognitive abilities that appeared to be most affected by CTC treatment.

The investigators also note that changes in cognitive function were not influenced by the subjects’ menopausal status or reports of fatigue, anxiety or depression.

SOURCE: Journal of the National Cancer Institute, December 6, 2006.

RELATED STORIES:
MU Researchers Recommend Exercise for Breast Cancer Survivors, Lymphedema Patients   Research advances breast reconstruction   Scientists discover powerful biomarker panel for the early detection of breast cancer   Resetting Biological Clock May Help Prevent Breast Cancer   One in Five Breast Cancer Patients May Not Adhere to Hormone Therapy   Metabolic syndrome predicts breast cancer relapse   Breast cancer kills more black women   Emerging research heralds new era of breast cancer management   Higher co-payments increase chance of early discontinuation of breast cancer therapy   Community health worker interventions improve rates of US mammography screening   Less than Half of Breast Cancer Patients Follow Hormone Therapy   Few women take tamoxifen to prevent breast cancer   Team identifies new breast cancer tumor suppressor and how it works   Blacks only face survival gap with some cancers   Obesity raises overall risk of breast cancer   New Guideline Will Improve Hormone Receptor Testing for Patients with Breast Cancer   Mammographic density and risk of breast cancer   Dieting reduces lymphedema after breast cancer   Antibiotic Slows Growth of Bladder, Breast Cancer Cells   Excess pounds may dim breast cancer prognosis   Breast Cancer Risk Found High After Chest Radiation for Hodgkin’s   Computer Based Model Helps Radiologists Diagnose Breast Cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]